Press Release Details

Cerus Corporation Receives Milestone Payment From BioOne

December, 26 2006

European CE Mark Approval for the INTERCEPT Blood System for Plasma Prompts Event

CONCORD, Calif. -- Cerus Corporation (NASDAQ:CERS) announced today the receipt of a $5 million cash milestone payment from BioOne Corporation. The milestone payment was prompted by Cerus' recent receipt of CE mark regulatory approval for the INTERCEPT Blood System for plasma in Europe. In addition to the cash payment, Cerus expects to receive an additional milestone payment of BioOne preferred stock worth $5 million in early 2007 pursuant to the terms of its agreement with BioOne. Upon receipt of the cash milestone payment, Cerus forwarded $0.5 million to Baxter Healthcare Corporation in accordance with an agreement relating to the BioOne commercialization rights.

BioOne has commercialization rights for the INTERCEPT Blood System for platelets and plasma in parts of Asia. The agreements between Cerus and BioOne provide for milestone payments to Cerus, as well as royalties based upon sales of the INTERCEPT Blood System for platelets and plasma.


Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in research and development of prophylactic and therapeutic vaccines for infectious diseases. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology and is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

This press release contains forward-looking statements. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed forward-looking statements, including, without limitation, statements including references to the receipt of milestone payments, and the timing thereof. Words such as "estimate," "expect" and similar words or expressions or the negative of these words or expressions are intended to identify forward-looking statements. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, the risk that the offering will not be completed due to failure to satisfy the closing conditions related to the offering or other reasons, as well as other risks detailed in the company's filings with the Securities and Exchange Commission, including the company's Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2006. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600